Diagnostic value of tubular and glomerular biomarkers across different stages of kidney injury in patients with type 2 diabetic nephropathy - Scorecard - MDSpire
Advertisement
Diagnostic value of tubular and glomerular biomarkers across different stages of kidney injury in patients with type 2 diabetic nephropathy
Clinical Scorecard: Evaluating the Diagnostic Utility of Urinary Tubular and Glomerular Biomarkers at Various Stages of Kidney Damage in Individuals with Type 2 Diabetic Nephropathy
At a Glance
Category
Detail
Condition
Diabetic Nephropathy (DN)
Key Mechanisms
Urinary glomerular and tubular biomarkers reflect distinct anatomic compartments and pathophysiologic processes in kidney injury.
Target Population
Hospitalized patients with Type 2 Diabetes Mellitus (T2DM)
Care Setting
Multicenter hospitals
Key Highlights
Urinary biomarkers significantly elevated in DN, detectable even in eGFR category G1.
UACR showed the highest single-marker discrimination for DN.
A combined model of UACR, urinary β2-microglobulin, and N-acetyl-β-D-glucosaminidase improved diagnostic performance.
Urinary β2-microglobulin performed best for stage discrimination.
Study emphasizes the need for complementary biomarkers beyond albuminuria.
Guideline-Based Recommendations
Diagnosis
Utilize urinary glomerular and tubular biomarkers for identifying DN.
Management
Integrate tubular injury markers with UACR for improved diagnostic performance.
Monitoring & Follow-up
Consider stage-wise behavior of biomarkers across KDIGO eGFR categories.
Risks
Heterogeneous kidney injury in T2DM may limit sensitivity of albumin-centered screening strategies.
Patient & Prescribing Data
320 hospitalized patients with T2DM, including 160 with DN.
Focus on urinary biomarkers to enhance early detection and characterization of DN.
Clinical Best Practices
Employ a combination of urinary biomarkers for accurate diagnosis and staging of DN.
Monitor eGFR and albuminuria alongside tubular biomarkers for comprehensive risk assessment.
US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.
